Zanzalintinib - HY-138696
Nur noch %1 verfügbar
Catalog #
HY-138696
Ab
93,00 €
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research[1][2].
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-138696/Zanzalintinib-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | Cancer-Kinase/protease |
| Alternative Names | XL092 |
| CAS | 2367004-54-2 |
| Storage | 4°C (Powder, protect from light) |
| MWT | 528.53 |
| Solubility | DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C) |
| Clinical Information | Phase 3 |
| Target | c-Met/HGFR;TAM Receptor;VEGFR |
| Application: | Cancer-Kinase/protease |
|---|